Celebrating Innovation in Eye Care
Oculis Holding AG (Nasdaq: OCS) has teamed up with EURETINA to mark a significant achievement in ophthalmology—the creation of the Ramin Tadayoni Award. This esteemed award, revealed in Zug, Switzerland, honors the impactful work of Professor Ramin Tadayoni, a highly esteemed retina expert and Chief Scientific Officer at Oculis, who tragically passed away earlier this year.
About the Ramin Tadayoni Award
The Ramin Tadayoni Award is designed to recognize and inspire the next generation of researchers committed to making strides in retinal studies. It pays homage to Professor Tadayoni’s incredible legacy, highlighting the importance of innovation in eye care research. The first recipient of the award is Andrea Govetto, M.D., Ph.D., whose pioneering research focuses on developing a computational model to analyze fluid flow and tissue deformation in macular edema, an essential area in ophthalmology.
Recognizing Exceptional Talent
Anat Loewenstein, M.D., President of EURETINA, expressed her appreciation to the applicants who submitted more than 50 competitive proposals for this award. Dr. Loewenstein congratulated Dr. Govetto, noting that his research aligns seamlessly with the contributions made by Professor Tadayoni to the field.
Insights from the CEO
Riad Sherif, M.D., Chief Executive Officer of Oculis, shared his perspective on the collaboration for this award, stating, “We are proud to be part of this initiative alongside EURETINA and extend our sincere congratulations to Dr. Govetto. His commitment to enhancing research on retinal diseases and improving patient care truly embodies the spirit of this award.”
A Promising Future for Retina Research
Dr. Andrea Govetto is a skilled vitreoretinal surgeon at the Oftalmico-Fatebenefratelli Hospital in Milan, Italy. He has dedicated his work to understanding the complexities of retinal pathology, especially concerning retinal detachment and the intricate issues surrounding lamellar macular holes and epiretinal membranes. His extensive training encompasses a specialization in ophthalmology in Spain and clinical fellowships at the prestigious Stein Eye Institute at UCLA and the Bristol Eye Hospital in the U.K.
The Award Ceremony
This annual award not only offers significant financial support, providing €30,000 for ongoing research efforts and an extra €5,000 for the awardee, but it also nurtures the next generation of outstanding ophthalmologists focused on retina innovation. The award was presented at the opening ceremony of the EURETINA congress, an important event for ophthalmology professionals taking place over several days in Barcelona.
About Oculis
Oculis is a forward-thinking biopharmaceutical company dedicated to improving eye health through innovative research. With a diverse pipeline that includes promising candidates like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, Oculis aims to enhance the quality of life for patients around the globe. Headquartered in Switzerland, the company operates in both the U.S. and Iceland, supported by a strong management team and distinguished healthcare investors who share its vision for advancing ophthalmic care.
Reaching Out to Oculis
For further information about Oculis and its research projects, interested parties can connect with the company through various channels. Ms. Sylvia Cheung, the CFO, is available for inquiries, and additional media relations contact details can be found through their dedicated channels.
Frequently Asked Questions
What is the Ramin Tadayoni Award?
The Ramin Tadayoni Award honors innovative research in retinal health, recognizing outstanding young ophthalmologists.
Who was the first recipient of the Ramin Tadayoni Award?
Andrea Govetto, M.D., Ph.D., was awarded for his work on fluid flow and retinal tissue deformation in macular edema.
What did Dr. Govetto's research focus on?
His research centers on understanding fluid dynamics and tissue changes associated with retinal diseases, notably macular edema.
What financial support does the award offer?
The annual award provides €30,000 for research support and an additional €5,000 for the awardee.
How does Oculis contribute to eye care?
Oculis develops innovative biopharmaceutical solutions aimed at improving sight and treating various ocular conditions.
